Abbvie Corporation v. Janssen Inc., 2014 FC 55 (Ustekinumab*)

Justice Hughes - 2014-01-17

Read full decision. Automatically generated summary:

This is an action respecting the infringement and validity of a patent directed to human antibodies that bind a human cytokine known as interleukin 12 or IL-12. This binding tends to neutralize some of the effects of IL-12 and, and thus is useful in the treatment of diseases; in particular, psoriasis. Two claims of the patent are at issue. A principal ground of contention is the scope of those claims which are directed to human antibodies with particular characteristics as to affinity and potency are too broadly drafted so as to cover more than was actually invented or could properly be claimed. (See also last week's blog post on this decision.)

Decision relates to:


Canadian Intellectual Property